INSMED INC (1INSM.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1INSM - US4576693075 - Common Stock
1INSM.MI Key Statistics, Chart & Performance
The current stock price of 1INSM.MI is 133 EUR.
1INSM.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1INSM.MI.
1INSM.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1INSM.MI. The financial health of 1INSM.MI is average, but there are quite some concerns on its profitability.
1INSM.MI Financial Highlights
Over the last trailing twelve months 1INSM.MI reported a non-GAAP Earnings per Share(EPS) of -5.27. The EPS decreased by -11.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.15% | ||
| ROE | -125.2% | ||
| Debt/Equity | 0.77 |
1INSM.MI Forecast & Estimates
25 analysts have analysed 1INSM.MI and the average price target is 185.76 EUR. This implies a price increase of 39.67% is expected in the next year compared to the current price of 133.
For the next year, analysts expect an EPS growth of -11.32% and a revenue growth 51.41% for 1INSM.MI
1INSM.MI Ownership
About 1INSM.MI
Company Profile
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 1,271 full-time employees. The company is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Company Info
INSMED INC
700 Us Highway 202/206
Bridgewater NEW JERSEY US
Employees: 1271
Phone: 19089779900
INSMED INC / 1INSM.MI FAQ
Can you describe the business of INSMED INC?
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 1,271 full-time employees. The company is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Can you provide the latest stock price for INSMED INC?
The current stock price of 1INSM.MI is 133 EUR. The price decreased by -6.34% in the last trading session.
What is the dividend status of INSMED INC?
1INSM.MI does not pay a dividend.
What is the ChartMill rating of INSMED INC stock?
1INSM.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting 1INSM stock to perform?
25 analysts have analysed 1INSM.MI and the average price target is 185.76 EUR. This implies a price increase of 39.67% is expected in the next year compared to the current price of 133.
Can you provide the PE ratio for 1INSM stock?
INSMED INC (1INSM.MI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.27).
Is INSMED INC (1INSM.MI) expected to grow?
The Revenue of INSMED INC (1INSM.MI) is expected to grow by 51.41% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.